Louisiana State Employees Retirement System Buys New Stake in Krystal Biotech, Inc. (NASDAQ:KRYS)

Louisiana State Employees Retirement System bought a new stake in Krystal Biotech, Inc. (NASDAQ:KRYS) during the second quarter, according to its most recent disclosure with the SEC. The firm bought 12,500 shares of the company’s stock, valued at approximately $2,296,000.

Other hedge funds have also recently modified their holdings of the company. Scout Investments Inc. purchased a new position in shares of Krystal Biotech in the 1st quarter valued at $8,976,000. Fiera Capital Corp purchased a new position in shares of Krystal Biotech in the 4th quarter valued at $1,973,000. Sei Investments Co. grew its position in shares of Krystal Biotech by 128.3% in the 1st quarter. Sei Investments Co. now owns 33,752 shares of the company’s stock valued at $6,005,000 after buying an additional 18,968 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Krystal Biotech by 1.5% in the 4th quarter. Vanguard Group Inc. now owns 2,435,774 shares of the company’s stock valued at $302,182,000 after buying an additional 35,632 shares during the last quarter. Finally, Janney Montgomery Scott LLC purchased a new position in shares of Krystal Biotech in the 1st quarter valued at $3,175,000. 86.29% of the stock is owned by hedge funds and other institutional investors.

Krystal Biotech Price Performance

Shares of KRYS stock traded up $4.98 during mid-day trading on Friday, hitting $202.50. The stock had a trading volume of 77,493 shares, compared to its average volume of 364,976. Krystal Biotech, Inc. has a fifty-two week low of $93.95 and a fifty-two week high of $219.34. The firm has a market cap of $5.78 billion, a PE ratio of 107.02 and a beta of 0.84. The company’s 50-day simple moving average is $191.10 and its 200-day simple moving average is $169.79.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Monday, August 5th. The company reported $0.53 EPS for the quarter, topping the consensus estimate of $0.50 by $0.03. The firm had revenue of $70.28 million during the quarter, compared to analyst estimates of $65.27 million. During the same quarter last year, the business posted ($1.25) EPS. The firm’s revenue was up 70283900.0% on a year-over-year basis. On average, analysts expect that Krystal Biotech, Inc. will post 2 EPS for the current year.

Insider Activity at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, June 11th. The shares were sold at an average price of $175.76, for a total value of $4,394,000.00. Following the completion of the sale, the insider now owns 1,525,882 shares in the company, valued at $268,189,020.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 14.10% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the stock. Citigroup reissued a “neutral” rating and set a $204.00 price objective (up from $195.00) on shares of Krystal Biotech in a research report on Tuesday, August 6th. Chardan Capital raised their price objective on shares of Krystal Biotech from $153.00 to $208.00 and gave the stock a “buy” rating in a research report on Monday, August 5th. Evercore ISI raised their price objective on shares of Krystal Biotech from $201.00 to $206.00 and gave the stock an “outperform” rating in a research report on Monday, August 12th. Finally, HC Wainwright reissued a “buy” rating and set a $200.00 price objective on shares of Krystal Biotech in a research report on Monday, August 5th. One analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $187.89.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).